Inmune Bio (INMB) Other financing activities (2021 - 2025)

Inmune Bio (INMB) posted Other financing activities of $1000.0 for Q1 2025, down 96.67% sequentially from $30000.0 in Q1 2022.

Inmune Bio (INMB) Other financing activities (2021 - 2025) Analysis & Trends

Inmune Bio has reported Other financing activities for 3 years, with the latest figure at $1000.0 in Q1 2025.

Quarterly Other financing activities changed N/A year-over-year to $1000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $1000.0 (changed N/A YoY) and the FY2025 annual result came in at $1000.0, down 99.76% from the prior year.
Other financing activities slipped to $1000.0 in Q1 2025 per INMB's latest filing, from $30000.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.1 million in Q3 2021 and troughed at $1000.0 in Q1 2025.
A 3-year average of $291500.0 and a median of $24000.0 in 2021 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 66.67% in 2022, down 66.67% in 2022.
Over 3 years, Other financing activities stood at $1.1 million in 2021, then plunged by 97.31% to $30000.0 in 2022, then slumped by 96.67% to $1000.0 in 2025.
According to Business Quant data, Other financing activities over the past three periods registered $1000.0, $30000.0, and $1.1 million for Q1 2025, Q1 2022, and Q3 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Inmune Bio	61.59 Mn	43.18 Mn	-

Download Data